Euthymics’ technology allows us to “tune” the interactions of 5-HT, NE and DA transporters with single molecules having varying ratios of affinity for the three transporters. With this tuning we can optimize efficacy while minimizing side effects.





By changing the ratios of multiple transporter affinities in a single compound it is hoped that symptoms of the target disorder can be improved, while reducing the side-effects often seen with a compound which only modulates the reuptake of one of the monoamines. By way of example, Euthymics Bioscience’s lead compound amitifadine (ATN) addresses key issues involved with addiction.


Mechanism of Action in Addiction

DOPAMINE: affects craving     NOREPINEPHRINE: acts on impulsivity     SEROTONIN: affects mood

Serotonin reputake inhibitors (SSRIs) have been used to alleviate symptoms of anxiety and depression that accompany withdrawal. By overlaying norepinephrine and dopamine on the role of serotonin, it is believed that amitifadine has the potential to reduce addictive behavior while reducing withdrawal effects that can limit compliance with medication. Improvement in treatment adherence is a major goal of treatment.